Noncancer Pain

• FDA approval · 2023-12-15
  FDA Approved: XTAMPZA ER — Supplemental Application (Collegium Pharmaceutical, Inc.)

  The FDA approved a supplemental application for XTAMPZA ER (oxycodone) submitted by Collegium Pharmaceutical, Inc., updating the product's l…

• FDA approval · 2021-03-04
  FDA Approved: BELBUCA — Supplemental Application (BioDelivery Sciences International Inc)

  The FDA approved a supplemental application for Belbuca (buprenorphine HCl buccal film) submitted by BioDelivery Sciences International, Inc…

• FDA approval · 2020-04-13
  FDA Approved: MOVANTIK — Supplemental Application (RedHill Biopharma Ltd)

  The FDA approved a supplemental application for Movantik (naloxegol oxalate) submitted by RedHill Biopharma Ltd.

• FDA approval · 2018-02-28
  FDA Approved: MOVANTIK — Supplemental Application (RedHill Biopharma Ltd)

  FDA approved a supplemental application for MOVANTIK (naloxegol oxalate) filed by RedHill Biopharma Ltd.

• FDA approval · 2016-08-22
  FDA Approved: MOVANTIK — Supplemental Application (RedHill Biopharma Ltd)

  FDA approved a supplemental application for Movantik (naloxegol oxalate) from RedHill Biopharma Ltd.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2014-04-16
  FDA Approved: MS CONTIN — Supplemental Application (Rhodes Pharmaceuticals L.P.)

  The FDA approved a supplemental application for MS CONTIN (morphine sulfate) filed by Rhodes Pharmaceuticals L.P., signaling an update relat…